NIMBLE Diagnostics is heading to Paris, France this Autumn ✈️ We’re proud to announce that we have been chosen to pitch at the European Innovation Council and SMEs Executive Agency (EISMEA) & Johnson & Johnson #HealthTech Investor Day – powered by EuroQuity - Bpifrance. Here’s to a great opportunity to meet expert investors looking for the best #biotech #pharmaceuticals #digital #medtech solutions and take our fundraising journey one step further. Interested in hearing our pitch and connecting at the event? Investors can still register to join the event ➡️ https://lnkd.in/eVtBwHsG We will be participating alongside EVerZom, ELEM Biotech, Gate2Brain, PannTheraPi, Nectin Therapeutics, EyeControl, AdjuCor GmbH, STENTiT, BOYDSense, Angiolutions and others.
NIMBLE Diagnostics
Investigación biotecnológica
Barcelona, Catalonia 1305 seguidores
We are developing novel non-invasive technologies to improve the life of millions of patients with implanted stents
Sobre nosotros
Stents are one of the most implanted devices in the world, and are used to restore the correct flow of blood or other fluids. Stents are especially useful to prevent heart attacks or to treat its lasting symptoms, but once implanted can become blocked or damaged, which occur in almost a third of the cases. This progression occurs gradually, but symptoms appear only after the stent is already 90% occluded, which is too late to prevent worsening conditions. Then, in most cases, clinicians need to perform an invasive procedure called angiography, which consists in inserting a catheter into the artery to directly inspect the stent. Obviously, this is a very complex and invasive procedure, where the patient needs anesthesia, lots of X-ray exposure and a 24h hospitalization recovery. Moreover, this is very expensive, as you need highly trained staff, bedding care and expensive reagents. All of this leads to a situation where clinicians cannot act upon the problem until it has already manifested, which increases the incidence of serious complications, including strokes, heart attacks or sudden death, which could be otherwise preventable. In order to change this situation, we are developing a microwave-based technology that can read the electromagnetic signature of the stent non-invasively. Our main objective is to be able to measure and monitor any issue with in-stent restenosis, thrombosis or stent fractures. All of these characteristics translate into a product, the NIMBLE system, which will enable early treatments to prevent negative outcomes. Medication compliance c ouldbe identified and managed, symptoms could be correlated with stent function, and triggers of cardiac events could be found before it is too late. We are developing micro-wave based technologies to monitor the functional integrity of stents
- Sitio web
-
www.dxnimble.com
Enlace externo para NIMBLE Diagnostics
- Sector
- Investigación biotecnológica
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- Barcelona, Catalonia
- Tipo
- De financiación privada
- Fundación
- 2022
Ubicaciones
-
Principal
Barcelona, Catalonia 08916, ES
Empleados en NIMBLE Diagnostics
Actualizaciones
-
NIMBLE Diagnostics ha compartido esto
📢 ¡Anunciamos a los semifinalistas de EIT Health Catapult 2024-25! Estamos encantados de anunciar las 30 startups seleccionadas para las semifinales de la 9ª edición de EIT Health Catapult. En esta edición 5 de las 30, han sido españolas: Aptadel Therapeutics, mjn-neuro, NIMBLE Diagnostics, Rejuversen y The Blue Box Biomedical Solutions Est@s innovadores, que abarcan las ciencias de la vida y la tecnología sanitaria, mostrarán sus soluciones para cambiar vidas a los mejores expertos del sector, inversores y homólogos de toda Europa. ¡Felicidades a tod@s! ✨Puntos y fechas destacadas: - Presentaciones semifinales: 10 Life Sciences & 20 Healthtech startups presentarán ante una audiencia pública de profesionales de la salud, inversores y expertos. - Anuncio de las finales en abril de 2025: Las 9 mejores startups (3 de ciencias de la vida y 6 de tecnología sanitaria) pasarán a la fase final, en la que competirán por un premio de 30.000 euros y mentoría. - Premios especiales: Premios de la industria por un total de más de 800.000 euros de grandes nombres como Amazon Web Services (AWS), eg technology Ltd, Lusíadas Saúde, AstraZeneca, y el prestigioso «EIT Health Catapult Audience Alex Casta Award» 🏆. 🎉 El programa EIT Health Catapult tiene un legado de empoderamiento de startups con apoyo y mentoría de alto impacto, evaluación empresarial rigurosa y oportunidades de networking sin precedentes. A lo largo de ocho ediciones, Catapult ha ayudado a más de 330 empresas a conseguir inversiones de varios millones de euros y el apoyo vital de socios europeos clave. 👉 No te pierdas cómo estas startups superan los retos, inspiran el cambio y compiten por ser el centro de atención europeo en innovación sanitaria: https://lnkd.in/eudWYHEj
📢 Exciting News! EIT Health Catapult 2024-25 Semi-Finalists Announced! We’re thrilled to unveil the 30 groundbreaking start-ups selected for the semi-finals of the 9th edition of the EIT Health Catapult! They are: Aptadel Therapeutics, ArrayPatch Ltd, Cellectric Biosciences, Fusix Biotech GmbH, Immunofusion, Nūmi, PepKon, PoliRNA, Rejuversen, You2Yourself, Antegenes, BrightComSol, Brightmind.AI, CC Diagnostics, CheckEye, cureVision GmbH, Custom Surgical, DIGESTAID - Digestive Artificial Intelligence Development, FindAir, Galenband, Healshape, Kinetic Cortex, Lifebloom, mjn-neuro, NimBio, NIMBLE Diagnostics, PsyCurio, The Blue Box Biomedical Solutions, Tympany Medical , and VitalSigns Oy. These innovators, spanning life sciences and healthtech, are set to showcase their life-changing solutions to top industry experts, investors, and peers from across Europe. ✨ Key Highlights: - Semi-Final Presentations: 10 Life Sciences & 20 Healthtech start-ups will present to a public audience of healthcare professionals, investors, and experts. - Finals Announcement in April 2025: Top 9 start-ups (3 Life Sciences & 6 Healthtech) will advance to the finals, competing for a €30,000 prize and valuable in-kind support. - Major Prizes: Industry in-kind prizes totaling over €800,000 from top names like Amazon Web Services (AWS), eg technology Ltd, Lusíadas Saúde, AstraZeneca, and the prestigious "EIT Health Catapult Audience Alex Casta Award" 🏆 🎉 The EIT Health Catapult programme has a legacy of empowering start-ups with high-impact mentorship, rigorous business assessment, and unparalleled networking opportunities. Over eight editions, Catapult has supported 330 companies in securing multi-million euro investments and vital support from key European partners. 👉 Stay tuned as these start-ups push boundaries, inspire change, and compete for Europe’s spotlight in healthcare innovation: https://lnkd.in/eudWYHEj #EITHealthCatapult #HealthcareInnovation #LifeSciences #Healthtech #StartUps
-
✨ Exciting News from NIMBLE Diagnostics! ✨ We're honored to have been selected to participate in the Spain Up Nation 101 event earlier this week, organized by FORO ADR and Enisa con el emprendimiento innovador in the stunning city of Córdoba—home to four UNESCO World Heritage Sites. Alongside us were some incredible Catalan start-ups: D-Sight S.L., Integra Therapeutics, MiMARK, Kreios Space, Pack2Earth, Pangea Aerospace, and Robopedics. A special congratulations to Robopedics for being chosen as the Catalan representative! The event also highlighted the many inspiring female entrepreneurs driving innovation in Catalunya. 🌟 We’re especially grateful to Rocío Flor and ACCIÓ for their invaluable support and for championing our project. Thank you for the opportunity and for celebrating innovation with us!
-
NIMBLE Diagnostics ha compartido esto
EIC Investment Advisor / eMBA candidate Food & Agribusiness Wageningen & TIAS / Fellow Newton Venture Program
⏳ The #EUeic Investor Day on Healthcare with Johnson & Johnson powered by EuroQuity - Bpifrance is just in few days. We continue the introduction of the companies selected by the prestigious jury of investors to pitch within the #Medtech session. 1️⃣ AMT Medical, revolutionizes heart bypass surgery, eliminating the need for open-heart procedures and enabling same-day discharge for patients. 2️⃣ Angiolutions GmbH, revolutionizes AAA treatment with a first-of-its-kind device that stops AAA growth early. Bringing new hope to thousands of patients without a treatment option. 3️⃣ BOYDSense is an award-winning startup pioneering non-invasive breath analysis solutions for biomarker screening, monitoring, and detection. 4️⃣ INBRAIN Neuroelectronics, develops high precision BCI therapeutics using graphene and AI to restore neural function in real time. 5️⃣ NIMBLE Diagnostics, is developing the WAEVE™ System, a medical device using MWI for non-invasive monitoring of stent patients, regardless of type or location. 6️⃣ O11 biomedical GmbH, improves lives by addressing hypercapnic lung failure. They developed RESPILIQ, which uses the gut as a respiratory organ. With promising results, they are funded to reach TRL 8. 7️⃣ STENTiT BV, develops regenerative stents that reconstruct arteries from the inside-out with the goal to become the new standard for endovascular reconstruction. 🤝 Investors - you are invited to meet them on 13 November in Paris - by registering at the link in the comments. #HealthTech #biotech #medtech #eicAccelerator #EUeic #Healthcare Stéphane Ouaki 🇺🇦🇪🇺 | Lilian Alcaraz | Pascal Lagarde | Anna Stodolkiewicz, CFA, | Marielle Mailhes | Gilles Le Cocguen, | María Cristina Chumacero | Oana Popescu | Agnieszka Stasiakowska | Justyna Tisserand | Vilma Radvilaite | André Moraes Sarmento | Ana Moura | Jan Bernlöhr | Mariana Domingues | Pedro Amaral Carvalho | Louis Segers | Dealflow.eu | EurA AG
-
NIMBLE Diagnostics ha compartido esto
💡¿Qué tienen en común tecnologías para el #healthtech💉, la #sostenibilidad♻ o la #construccion 🏗 ? Que todas son deep tech y buscan mejorar la calidad de las soluciones ofrecidas, tal y como lo demostraron ayer algunas de nuestras #startups en el Barcelona Deep Tech Summit 🌐 🎤 Allí acompañamos sobre el escenario a José Solá Gomeza de diip Artificial Intelligence, Manuel Villa-Arrieta de Biyiud, Sustainability as Wealth y Oriol Iborra Egea, PhD de NIMBLE Diagnostics quienes presentaron sus proyectos y pudimos conocer de cerca sus prometedores e innovadores desarrollos. ✨ 🙌 También nos encontramos con otros socios que no se perdieron la cita y tenían representación en el Smart City Expo World Congress: ARCbcn, Enginyeria & Innovació - WATTEGA, BEAMAGINE S.L., SITEP y Seabots ¡Un placer saludaros a todos! 🔗 ¿Te interesa formar parte de nuestro ecosistema y conectar con otros líderes en deep tech? Contacta con nosotros: https://lnkd.in/dc9D9wiZ
-
NIMBLE Diagnostics ha compartido esto
30 start-up innovantes ont été sélectionnées pour les demi-finales de l'EIT Health Catapult, saison 2024-2025 ! 🚀 Parmi elles, quelques pépites françaises 🇫🇷 🐓 : - Côté healthtech, Healshape et Lifebloom; - Et pour les lifesciences, Nūmi et PepKon. 🏆 Félicitations à elles, ainsi qu'aux 26 autres demi-finalistes : Aptadel Therapeutics, ArrayPatch Ltd, Cellectric Biosciences, Fusix Biotech GmbH, Immunofusion, PoliRNA, Rejuversen, Urimon onderzoek, Antegenes, BrightComSol, Brightmind.AI, CC Diagnostics, CheckEye, cureVision GmbH, Custom Surgical, DIGESTAID - Digestive Artificial Intelligence Development, FindAir, Galenband, Kinetic Cortex, mjn-neuro, Nimbio, NIMBLE Diagnostics, PsyCurio, The Blue Box Biomedical Solutions, Tympany Medical et VitalSigns Oy. En savoir plus 👉 https://lnkd.in/eudWYHEj - #eithealthcatapult #eithealth #santé #innovation EIT Health France, bioRN Life Science Cluster Rhine-Neckar, Medical Valley EMN e. V.
EIT Health Catapult 2024-25 selects 30 semi-finalists - EIT Health
https://eithealth.eu
-
NIMBLE Diagnostics ha compartido esto
En ITEMAS tenemos la misión de conseguir que la innovación sanitaria llegue al Sistema Nacional de Salud y en esto hemos centrado nuestras sesiones de esta mañana que han contado con una representación nutrida y variada de empresas del sector. 💡 Hemos empezado discutiendo sobre si un PhD puede ser CEO de una spin-off en una mesa moderada por ESTELA SANCHEZ SIMON (Fundación para la Investigación Biomédica HULP) y Marga Nadal (Institut d'Investigació Biomèdica de Girona (IDIBGI). Hemos contado con tres visiones muy distintas: 🟢 Defendiendo el sí Oriol Iborra Egea, PhD, CEO de NIMBLE Diagnostics 🟠 Defendiendo el quizás Josep Lluís Falcó, CEO de GENESIS Biomed 🔴 Defendiendo el no, Raúl Martín-Ruiz, partner en Ysios Capital 🤝 Otra mesa se ha centrado en el rol de las instituciones en las empresas participadas en una mesa moderada por Lluís Blanch, coordinador de ITEMAS y Ramon Maspons Bosch (Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)). Hemos contado con las opiniones de Ana Rodríguez Cala, Laura Rodríguez Gallego (Invivo Partners), Rafael Mañez Mendiluce (RemAb Therapeutics) y Yolanda Puiggròs Jiménez de Anta (PwC España).. 🤝 Por último, nos hemos centrado en un sector concreto, la innovación en farma, con representantes de importantes empresas farmacéuticas como César Velasco Muñoz (AstraZeneca), Amelia Martín Uranga (Farmaindustria), Diego Guinea (Eli Lilly and Company) y Pablo Hervás Ballesteros (GSK). Moderada por Javier de Castro Carpeño y Daniel Ruiz Iruela, subdirector general del Instituto de Salud Carlos III. 🔝 ¡Una mañana muy productiva para seguir profundizando en todos los aspectos de la innovación en salud y su transferencia tecnológica!
-
Our executive team had a fantastic experience at the #TCT2024 Conference in Washington DC, from October 29-31! It was an invaluable opportunity to showcase our WAEVE System to the American Interventional Cardiology community. Our team was thrilled to engage with leading strategists and experts interested in the latest advancements in non-invasive coronary stent occlusion monitoring. Special thanks to Dr. Peter Fitzgerald from Stanford University School of Medicine, Andrew Sharp from Mater Misericordiae University Hospital, Dublin, Dr. Mahesh Madhavan from Columbia University, and many others for their support and insights! We’re excited about the potential of this next-gen technology in enhancing healthcare in patients with coronary stents and improving clinical outcomes! #TCT2024 #CoronaryStents #WAEVESystem #CardiologyInnovation #HealthcareTech
-
🚨 New Article on NIMBLE’s Website! 🚨 We’re excited to share our latest article, reviewed by @HorstSievert: "Recovery After Heart Attack and Stent Implantation: A Comprehensive Guide." In this piece, we cover essential insights for post-stent recovery, from diet tips to exercise recommendations. Whether you’re a patient, caregiver, or healthcare provider, this guide offers valuable information to support a smoother, healthier recovery process. Read it now and learn more about what to expect after a heart attack and stent implantation. 💙 https://lnkd.in/gVGigdt8 #NIMBLEDiagnostics #HeartHealth #CardiovascularCare #RecoveryGuide #HealthcareInnovation
-
NIMBLE Diagnostics ha compartido esto
🗣️ It’s time to meet another one of Barcelona Deep Tech Summit speakers: Susana Amorós Garcia de Valdecasas She is a Telecommunications Engineer from Universitat Politècnica de Catalunya and holds a Master's in Computational Biomedical Engineering. She is a PhD candidate at UPC, where NIMBLE Diagnostics technology was born. With experience in infrastructure and cloud consulting solutions, she has worked on multidisciplinary projects related to the design of radiofrequency devices for medical use. Her research led to the NIMBLE Diagnostics technology from its inception, for which she is a co-inventor of the patent licensed to the Spin Off. Save the date! 📅 6/11 🕒 5:10 pm 🏢 Plenary session 🔗 Register now: https://lnkd.in/enFEybkv #barcelonadeeptechsummit #deeptech #BDTS24
Páginas similares
Buscar empleos
Financiación
Última ronda
Otorgar1.083.350,00 US$
Inversores
Grow Venture Partners